Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Viatris

How Is Viatris’ Stock Performance Compared to Other Biotech Stocks?

Over the past six months, Viatris has lagged behind its biotech peers, and Wall Street analysts continue to exercise caution regarding the stock's future outlook.

Barchart

Viatris Stock Outlook: Is Wall Street Bullish or Bearish?

As Viatris has trailed the broader market over the past year, analysts are skeptical about its future outlook.

Barchart

Here's What to Expect From Viatris' Next Earnings Report

Viatris is scheduled to release its fourth-quarter earnings next month, and analysts anticipate a profit dip.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Viatris Stock: Is VTRS Outperforming the Healthcare Sector?

Despite Viatris’ recent outperformance relative to its broader sector, Wall Street analysts remain cautious about the stock’s prospects.

Barchart

More ‘discreet’ Viagra-type drug could soon be available in Britain

US company Viatris has applied for a UK trademark for wafer-like film that dissolves in the mouth

The Guardian - UK

Viatris Shows Improved Relative Strength; Still Shy Of Benchmark

A Relative Strength Rating upgrade for Viatris shows improving technical performance. Will it continue?

Investors Business Daily

Viatris Gets Relative Strength Rating Upgrade

A Relative Strength Rating upgrade for Viatris shows improving technical performance. Will it continue?

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

2 Generic Drug Stocks Ready to Surge in 2025

Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success.

MarketBeat

Stocks With Rising Relative Strength: Viatris

A Relative Strength Rating upgrade for Viatris shows improving technical performance. Will it continue?

Investors Business Daily

Are Wall Street Analysts Predicting Viatris Stock Will Climb or Sink?

Due to Viatris’ underperformance relative to the broader S&P 500 Index over the past year, Wall Street analysts remain cautious about the stock’s prospects.

Barchart

Earnings Preview: What to Expect From Viatris' Report

Viatris is all set to announce its third-quarter results next month, with analysts predicting a double-digit decline in the company's earnings.

Barchart

How To Spot Good Value Stocks In A Sea Of Noise

Explore why traditional value investing often falls short and how catalysts can transform undervalued stocks into lucrative investments.

Barchart

Is Viatris Stock Underperforming the Dow?

Viatris has underperformed the Dow Jones Industrial Average over the past year, and analysts remain cautious about the stock’s prospects.

Barchart

Is Wall Street Bullish or Bearish on Viatris' Stock?

Viatris has underperformed the broader market over the past year, and Wall Street analysts are cautious about the stock’s prospects.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Viatris Quarterly Earnings Preview: What You Need to Know

Viatris is expected to release its fiscal second-quarter earnings next month, and analysts project a single-digit profit dip.

Barchart

Stocks Close Higher on Fed Rate Cut Optimism

The S&P 500 Index ($SPX ) (SPY ) Thursday closed up +0.51%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.85%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.16%. US stock indexes on Thursday settled higher, with the S&P 500 climbing to a...

Barchart

Stocks Rise on Fed Rate Cut Hopes

The S&P 500 Index ($SPX ) (SPY ) this morning is up +0.32%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.13%. US stock indexes this morning are moderately higher, with the S&P 500 climbing...

Barchart

Stocks Mixed as Weekly Jobless Claims Climb to an 8-1/2 Month High

The S&P 500 Index ($SPX ) (SPY ) this morning is down -0.04%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.12%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.27%. US stock indexes this morning are mixed, with the Dow Jones Industrials posing...

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Pharma Stocks Outperforming the Competition

The growing demand for innovative drugs, the use of advanced technologies, and growing global healthcare needs boost the pharmaceutical industry’s long-term growth prospects. Therefore, fundamentally strong pharma stocks Viatris (VTRS), Wave Life Sciences (WVE), and MEI Pharma (MEIP) might be ideal additions to your portfolio. Read on.

Investors Business Daily

These 9 Stocks Are Running To Start 2024

The S&P 500 rebounded last week near record highs, but is up just 0.2% so far in 2024. These are the index's top performers so far.

Investors Business Daily

60% Of This Year's Top Stocks Are In This Sector (It's Not Tech)

Just when it looked like technology stocks took over the S&P 500 — another sector is on the rise.

Investors Business Daily

Viatris Stock Bounds Higher As Divestitures Reach Nearly $7 Billion

Viatris stock popped Monday after the company announced it would divest most of its over-the-counter and women's health businesses.

The Independent UK

Stock market today: Asia mixed after Wall St rallies ahead of US inflation update

Asian stocks are mixed after Wall Street rallied and Japanese wages rose ahead of a U.S. inflation update that might influence Federal Reserve plans for possible interest rate hikes

Investors Business Daily

9 S&P 500 Stocks Are Screaming Buys According To The 'Fed Model'

Why deal with the S&P 500 when savings accounts pay 5%? That's exactly why many rich people are dumping stocks for cash.

Investors Business Daily

S&P 500 Stocks: Carnival, AMD Are Big Winners Today

Carnival led S&P 500 stocks Monday as optimism continues for cruise lines. AMD surged above an early buy point. Catalent was a big loser.

1 2

People

Daly

89 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

SP Global Market Intelligence

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.